About | Free Trial

Last Update

2016-06-15T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Lukaskrankenhaus

Background Information

Employment History

Coprincipal Investigator

BIOSOLVE-II

Affiliations

Board Member
EuroPCR

Member
European Society of Cardiology

Education

M.D.

Web References (124 Total References)


Concurrent with the presentation, the ...

citoday.com [cached]

Concurrent with the presentation, the positive data from BIOSOLVE-II supporting the device's safety and clinical performance were published by Principal Investigator Prof. Michael Haude, MD, et al online in The Lancet.

In May 2016, the company announced that 1-year data confirming long-term safety from the BIOSOLVE-II trial were presented by Prof. Haude at the EuroPCR 2016 conference and concurrently published online by Prof. Haude, et al in the European Heart Journal.
In the company's press release, Prof. Haude commented, "Now that clinical results have firmly established the safety and clinical performance of Magmaris, the magnesium-based scaffold could emerge as a strong alternative to currently available polymer-based scaffolds. Because it is made of magnesium, the scaffold has some unique advantages over polymer-based options in terms of deliverability and radial resistance following the implantation procedure. Prof. Haude is with Lukaskrankenhaus in Neuss, Germany.


Concurrent with the presentation, the ...

citoday.com [cached]

Concurrent with the presentation, the positive data from BIOSOLVE-II supporting the device's safety and clinical performance were published by Principal Investigator Prof. Michael Haude, MD, et al online in The Lancet.

In May 2016, the company announced that 1-year data confirming long-term safety from the BIOSOLVE-II trial were presented by Prof. Haude at the EuroPCR 2016 conference and concurrently published online by Prof. Haude, et al in the European Heart Journal.
In the company's press release, Prof. Haude commented, "Now that clinical results have firmly established the safety and clinical performance of Magmaris, the magnesium-based scaffold could emerge as a strong alternative to currently available polymer-based scaffolds. Because it is made of magnesium, the scaffold has some unique advantages over polymer-based options in terms of deliverability and radial resistance following the implantation procedure. Prof. Haude is with Lukaskrankenhaus in Neuss, Germany.


May 19, 2016-One-year data from the ...

citoday.com [cached]

May 19, 2016-One-year data from the BIOSOLVE-II trial of Biotronik's Magmaris magnesium-based, sirolimus-eluting bioresorbable scaffold were presented by Principal Investigator Prof. Michael Haude, MD, at the EuroPCR 2016 conference held May 17-20 in Paris, France. The data were concurrently published online by Prof. Haude et al in The European Heart Journal.

According to Biotronik, the study established the safety and clinical performance of the Magmaris device. Dr. Haude commented in the company's press release, "These results offer the first confirmation of Magmaris' longer-term safety and efficacy. BIOSOLVE-II demonstrates a promising potential of a magnesium-based approach to treating coronary artery disease as an alternative to polymer-based bioresorbable scaffolds. Dr. Haude is with the Lukaskrankenhaus in Neuss, Germany.


May 19, 2016-One-year data from the ...

citoday.com [cached]

May 19, 2016-One-year data from the BIOSOLVE-II trial of Biotronik's Magmaris magnesium-based, sirolimus-eluting bioresorbable scaffold were presented by Principal Investigator Prof. Michael Haude, MD, at the EuroPCR 2016 conference held May 17-20 in Paris, France. The data were concurrently published online by Prof. Haude et al in The European Heart Journal.

According to Biotronik, the study established the safety and clinical performance of the Magmaris device. Dr. Haude commented in the company's press release, "These results offer the first confirmation of Magmaris' longer-term safety and efficacy. BIOSOLVE-II demonstrates a promising potential of a magnesium-based approach to treating coronary artery disease as an alternative to polymer-based bioresorbable scaffolds. Dr. Haude is with the Lukaskrankenhaus in Neuss, Germany.


BIOTRONIK - Noticias - Comunicados de Prensa

www.biotronik.com [cached]

The two-year clinical data results of BIOSOLVE-I for the BIOTRONIK Drug Eluting Absorbable Metal Scaffold were presented by Professor Michael Haude, MD Lukaskrankenhaus, Neuss, Germany, one of the study's investigators.

...
The results from the BIOSOLVE-I study were presented at the European Course on Revascularization in Paris (EuroPCR) by Professor Michael Haude, Lukaskrankenhaus, Neuss, Germany.

Similar Profiles

Other People with this Name

Other people with the name Haude

Shay Haude
Austin Dental

Cyndi Haude
Klein Independent School District

Daniel Haude
Reminger Co

Lisa Haude
Paradigm Design Group LLC

Erica Haude
Tabor College

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory